Literature DB >> 10910992

The effects of TCDD on the activation of ovalbumin (OVA)-specific DO11.10 transgenic CD4(+) T cells in adoptively transferred mice.

D M Shepherd1, E A Dearstyne, N I Kerkvliet.   

Abstract

Exposure to the environmental contaminant 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) suppresses the generation of T cell-dependent immunity, both humoral and cell-mediated. However, the mechanism of TCDD-induced immune suppression remains to be defined. We hypothesized that exposure to TCDD suppresses the activation of naive CD4(+) T cells and prevents their expansion and differentiation into effector T-helper cells capable of driving T cell-dependent immune responses. To test this hypothesis, we adoptively-transferred DO11.10 OVA-specific T-cell receptor (TCR) transgenic T cells into syngeneic recipients and used a TCR-specific monoclonal antibody to track the in vivo activation of naive CD4(+) T lymphocytes following exposure to OVA. The production of OVA-specific antibodies was suppressed in a dose-dependent manner in adoptively transferred mice that had been exposed to TCDD. Although TCDD exposure had little effect on the expansion or activation of the adoptively transferred, OVA-specific CD4(+) T cells, these cells disappeared from the spleen more rapidly in TCDD-treated mice and produced significantly decreased levels of the T cell-derived cytokines IL-2 and IL-10. There was also a trend towards reduced IFN-gamma and IL-4 production following in vitro re-stimulation. These data suggest that TCDD may interfere with the survival and/or differentiation of OVA-specific T-helper cells. These results demonstrate for the first time the potential of the DO11.10 adoptive transfer system to directly assess immunotoxic effects of xenobiotics on antigen-specific CD4(+) T cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910992     DOI: 10.1093/toxsci/56.2.340

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  8 in total

Review 1.  Dioxin and immune regulation: emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells.

Authors:  Nikki B Marshall; Nancy I Kerkvliet
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

2.  Protection against lethal challenge with Streptococcus pneumoniae is conferred by aryl hydrocarbon receptor activation but is not associated with an enhanced inflammatory response.

Authors:  Beth A Vorderstrasse; B Paige Lawrence
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

3.  The Aryl Hydrocarbon Receptor Modulates T Follicular Helper Cell Responses to Influenza Virus Infection in Mice.

Authors:  Cassandra L Houser; B Paige Lawrence
Journal:  J Immunol       Date:  2022-04-20       Impact factor: 5.426

Review 4.  Role of the aryl hydrocarbon receptor (AhR) in lung inflammation.

Authors:  Celine A Beamer; David M Shepherd
Journal:  Semin Immunopathol       Date:  2013-08-21       Impact factor: 9.623

5.  Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole-4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3-[2-(2-phenylethyl)benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists.

Authors:  José Luis Morales; Jacek Krzeminski; Shantu Amin; Gary H Perdew
Journal:  Chem Res Toxicol       Date:  2008-01-08       Impact factor: 3.739

6.  2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) enhances placental inflammation.

Authors:  Morgan R Peltier; Yuko Arita; Natalia G Klimova; Ellen M Gurzenda; Hchi-Chi Koo; Amitasrigowri Murthy; Veronica Lerner; Nazeeh Hanna
Journal:  J Reprod Immunol       Date:  2013-05-01       Impact factor: 4.054

Review 7.  The aryl hydrocarbon receptor is a modulator of anti-viral immunity.

Authors:  Jennifer L Head; B Paige Lawrence
Journal:  Biochem Pharmacol       Date:  2008-11-05       Impact factor: 5.858

8.  Aryl Hydrocarbon Receptor-Mediated Perturbations in Gene Expression during Early Stages of CD4(+) T-cell Differentiation.

Authors:  Diana Rohlman; Duy Pham; Zhen Yu; Linda B Steppan; Nancy I Kerkvliet
Journal:  Front Immunol       Date:  2012-08-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.